Related Experiment Video
Updated: Aug 19, 2026
Skin Tattooing As A Novel Approach For DNA Vaccine Delivery
Published on: October 18, 2012
Antigen epitope-expressing cytokines for DNA immunization
Xianghui He1, Tom C Tsang, Tong Zhang
1Gene Therapy Group, Department of Microbiology and Immunology, PO Box 245049, University of Arizona, Arizona Health Sciences Center, Tucson, AZ 85724, USA.
Abstract:
Strategies to enhance the efficacy of DNA vaccination against malignancy remain to be established. In this study, a plasmid expressing a tumor antigen incorporated into the signal peptide of human IL-2 was tested as a DNA vaccine in a murine model system. Results showed that antigen-specific CTL responses were elicited by intramuscular injection of these plasmids. Importantly, compared with a minigene vector expressing the same epitope, the OVA epitope-incorporated, IL-2 expression plasmid vaccination was more effective in protecting mice from OVA-expressing tumor challenge. The improved efficacy appears to result from enhanced antigen presentation as well as the immunostimulatory activity of IL-2. This approach may provide new perspectives in designing cytokine-adjuvant DNA vaccines for clinical applications.
Insights
This study developed a novel DNA vaccine using a tumor antigen linked to IL-2. This enhanced DNA vaccine effectively protected mice against tumors by boosting immune responses, offering new possibilities for cancer vaccines.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Strategies for enhancing DNA vaccine efficacy against cancer are needed.
- Current DNA vaccines face challenges in eliciting robust anti-tumor immunity.
Purpose of the Study:
- To investigate a novel DNA vaccine strategy incorporating a tumor antigen with the IL-2 signal peptide.
- To evaluate the efficacy of this enhanced DNA vaccine in a murine cancer model.
Main Methods:
- A plasmid vector was constructed expressing a tumor antigen (OVA epitope) fused to the IL-2 signal peptide.
- The plasmid was administered via intramuscular injection in a murine model.
- Immune responses and tumor protection were assessed compared to a control minigene vector.
Main Results:
- The novel DNA vaccine successfully elicited antigen-specific cytotoxic T lymphocyte (CTL) responses.
- Mice vaccinated with the IL-2-linked antigen plasmid showed significantly improved protection against OVA-expressing tumor challenge compared to controls.
- Enhanced antigen presentation and IL-2's immunostimulatory effects contributed to the improved vaccine efficacy.
Conclusions:
- The developed DNA vaccine strategy, integrating a tumor antigen with IL-2, demonstrates enhanced anti-tumor efficacy.
- This cytokine-adjuvant DNA vaccine approach shows promise for clinical applications in cancer immunotherapy.
- Further research into designing advanced DNA vaccines for malignancy is warranted.
Related Concept Videos
01:26Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
00:42Cross-reactivity
01:28Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
01:10Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...